July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
June 2023 in “International journal of pharmaceutical quality assurance” Videodermoscopy is effective for diagnosing different types of non-scarring hair loss.
January 2024 in “Biomedicines” Using stem cells from hair follicles to treat female hair loss is safe and effective after six months.
36 citations
,
June 2014 in “International Journal of Dermatology” Dutasteride helps hair growth in those unresponsive to finasteride, but may cause more sexual dysfunction.
5 citations
,
October 2021 in “Vlaams Diergeneeskundig Tijdschrift” The protocol is easy to use, but reliable results need the same person to assess each time.
January 2026 in “Skin Research and Technology”
January 2026 in “Reactions Weekly” Both finasteride and dutasteride can cause sexual side effects, but they may differ in frequency and severity.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
6 citations
,
June 2021 in “EClinicalMedicine” ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
January 2007 in “Yearbook of Dermatology and Dermatologic Surgery” Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
2 citations
,
August 2016 37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
37 citations
,
February 2010 in “Psychoneuroendocrinology” Androgen self-administration might be controlled by membrane receptors, not nuclear ones.
January 2013 in “Journal of Chengdu Medical College” Tolterodine Tartrate effectively treats overactive bladder symptoms.
Thai plant extracts, especially Avicennia marina, can promote hair growth by inhibiting certain enzymes and boosting growth factors.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
December 2024 in “PubMed” TrichoFoam™ effectively delivers multiple hair loss treatments, maintaining their stability and effectiveness.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
January 2022 in “Journal of Pharmaceutical Negative Results” The VGG-SVM method accurately identifies and classifies stages of Alopecia Areata and other hair loss conditions.
April 2024 in “Dermatology reports” Dutasteride is more effective than finasteride for hair regrowth in male and female pattern hair loss, with similar side effects.
43 citations
,
May 1999 in “Journal of Biological Chemistry” Agouti protein affects melanocortin receptors through competitive antagonism and receptor down-regulation.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
April 2023 in “Cancer research” KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.